Title: Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Document date: 2019_10_15
ID: jkke8ije_677
Snippet: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, as monotherapy or in combination with chemotherapy, are effective in the treatment of metastatic colorectal cancer (mCRC). Current international guidelines recommend RAS (NRAS, KRAS) genetic testing as predictive biomarkers for response to anti-EGFR therapy. Only RAS wild-type tumors should be treated with anti-EGFR agents, as tumors with RAS mutations are unlikely to benefit.....
Document: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, as monotherapy or in combination with chemotherapy, are effective in the treatment of metastatic colorectal cancer (mCRC). Current international guidelines recommend RAS (NRAS, KRAS) genetic testing as predictive biomarkers for response to anti-EGFR therapy. Only RAS wild-type tumors should be treated with anti-EGFR agents, as tumors with RAS mutations are unlikely to benefit. We aimed to review the cost-effectiveness of RAS testing in mCRC patients prior to anti-EGFR therapy and to assess how well economic evaluations adhere to clinical practice guidelines.
Search related documents:
Co phrase search for related documents- anti egfr therapy and growth factor: 1, 2, 3
- anti egfr therapy and growth factor receptor: 1, 2, 3
- anti egfr therapy and mCRC colorectal cancer: 1
- anti egfr therapy response and colorectal cancer: 1
- chemotherapy combination and clinical practice guideline: 1
- chemotherapy combination and colorectal cancer: 1, 2, 3, 4, 5, 6, 7, 8
- chemotherapy combination and growth factor: 1, 2, 3
- chemotherapy combination and growth factor receptor: 1, 2, 3
- chemotherapy combination monotherapy and colorectal cancer: 1
- clinical practice guideline and growth factor: 1, 2
- clinical practice guideline and growth factor receptor: 1
- clinical practice guideline and international guideline: 1, 2, 3, 4, 5, 6, 7, 8
- colorectal cancer and cost RAS testing effectiveness: 1
- colorectal cancer and economic evaluation: 1
- colorectal cancer and genetic testing: 1, 2, 3, 4, 5, 6, 7
- colorectal cancer and growth factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- colorectal cancer and growth factor receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- colorectal cancer and international guideline: 1
- colorectal cancer and mCRC colorectal cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
Co phrase search for related documents, hyperlinks ordered by date